152 related articles for article (PubMed ID: 21532886)
1. Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer.
Liu Y; Norton JT; Witschi MA; Xu Q; Lou G; Wang C; Appella DH; Chen Z; Huang S
Neoplasia; 2011 May; 13(5):453-60. PubMed ID: 21532886
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anticancer activities of 6-amino amonafide derivatives.
Norton JT; Witschi MA; Luong L; Kawamura A; Ghosh S; Stack MS; Sim E; Avram MJ; Appella DH; Huang S
Anticancer Drugs; 2008 Jan; 19(1):23-36. PubMed ID: 18043127
[TBL] [Abstract][Full Text] [Related]
3. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J
Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047
[TBL] [Abstract][Full Text] [Related]
4. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
[TBL] [Abstract][Full Text] [Related]
5. Naphthalimides induce G(2) arrest through the ATM-activated Chk2-executed pathway in HCT116 cells.
Zhu H; Miao ZH; Huang M; Feng JM; Zhang ZX; Lu JJ; Cai YJ; Tong LJ; Xu YF; Qian XH; Ding J
Neoplasia; 2009 Nov; 11(11):1226-34. PubMed ID: 19881958
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel amonafide-polyamine conjugates as anticancer agents.
Wang Y; Zhang J; Li M; Li M; Xie S; Wang C
Chem Biol Drug Des; 2017 May; 89(5):670-680. PubMed ID: 27762101
[TBL] [Abstract][Full Text] [Related]
7. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Van Quaquebeke E; Mahieu T; Dumont P; Dewelle J; Ribaucour F; Simon G; Sauvage S; Gaussin JF; Tuti J; El Yazidi M; Van Vynckt F; Mijatovic T; Lefranc F; Darro F; Kiss R
J Med Chem; 2007 Aug; 50(17):4122-34. PubMed ID: 17658777
[TBL] [Abstract][Full Text] [Related]
8. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.
Xie L; Cui J; Qian X; Xu Y; Liu J; Xu R
Bioorg Med Chem; 2011 Jan; 19(2):961-7. PubMed ID: 21208805
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of new amonafide analogues via coupling reaction and their cytotoxic evaluation and DNA-binding studies.
Xie L; Xu Y; Wang F; Liu J; Qian X; Cui J
Bioorg Med Chem; 2009 Jan; 17(2):804-10. PubMed ID: 19070496
[TBL] [Abstract][Full Text] [Related]
10. Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating/methylating dual-action chimera Amonafidazene.
Walunj D; Thankarajan E; Prasad C; Tuchinsky H; Baldan S; Sherman MY; Patsenker L; Gellerman G
Eur J Med Chem; 2021 Dec; 225():113811. PubMed ID: 34507011
[TBL] [Abstract][Full Text] [Related]
11. Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres.
Kim DH; Choy T; Huang S; Green RM; Omary RA; Larson AC
Acta Biomater; 2014 Feb; 10(2):742-50. PubMed ID: 24161384
[TBL] [Abstract][Full Text] [Related]
12. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Freeman CL; Swords R; Giles FJ
Expert Rev Hematol; 2012 Feb; 5(1):17-26. PubMed ID: 22272701
[TBL] [Abstract][Full Text] [Related]
13. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
Mijatovic T; Mahieu T; Bruyère C; De Nève N; Dewelle J; Simon G; Dehoux MJ; van der Aar E; Haibe-Kains B; Bontempi G; Decaestecker C; Van Quaquebeke E; Darro F; Kiss R
Neoplasia; 2008 Jun; 10(6):573-86. PubMed ID: 18516294
[TBL] [Abstract][Full Text] [Related]
14. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
Mullane MR; Schilsky RL; Carroll RB; Wade JL; Kilton LJ; Blough RR; Bauman A; French SL; Benson AB
Invest New Drugs; 1994; 12(3):267-70. PubMed ID: 7896548
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
Tomczyk MD; Byczek-Wyrostek A; Strama K; Wawszków M; Kasprzycki P; Walczak KZ
Med Chem; 2019; 15(5):550-560. PubMed ID: 30207241
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
Felder TB; McLean MA; Vestal ML; Lu K; Farquhar D; Legha SS; Shah R; Newman RA
Drug Metab Dispos; 1987; 15(6):773-8. PubMed ID: 2893701
[TBL] [Abstract][Full Text] [Related]
18. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.
De Isabella P; Zunino F; Capranico G
Nucleic Acids Res; 1995 Jan; 23(2):223-9. PubMed ID: 7862525
[TBL] [Abstract][Full Text] [Related]
19. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Amonafide in dogs.
Lu K; McLean MA; Vestal ML; Newman RA
Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
